Literature DB >> 33487632

Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Dharminder Chauhan1, Kenneth C Anderson2, Arghya Ray3, Ting Du3, Yan Song3, Sara J Buhrlage4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33487632      PMCID： PMC8302665          DOI： 10.1038/s41375-021-01129-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors:  A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

2.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authors:  Dharminder Chauhan; Ze Tian; Benjamin Nicholson; K G Suresh Kumar; Bin Zhou; Ruben Carrasco; Jeffrey L McDermott; Craig A Leach; Mariaterresa Fulcinniti; Matthew P Kodrasov; Joseph Weinstock; William D Kingsbury; Teru Hideshima; Parantu K Shah; Stephane Minvielle; Mikael Altun; Benedikt M Kessler; Robert Orlowski; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

3.  Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Authors:  N E Franke; D Niewerth; Y G Assaraf; J van Meerloo; K Vojtekova; C H van Zantwijk; S Zweegman; E T Chan; C J Kirk; D P Geerke; A D Schimmer; G J L Kaspers; G Jansen; J Cloos
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

4.  Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.

Authors:  Sana Hibino; Shunsuke Chikuma; Taisuke Kondo; Minako Ito; Hiroko Nakatsukasa; Setsuko Omata-Mise; Akihiko Yoshimura
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

Review 5.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

Review 6.  Therapeutic advances in relapsed or refractory multiple myeloma.

Authors:  Kenneth C Anderson
Journal:  J Natl Compr Canc Netw       Date:  2013-05       Impact factor: 11.908

7.  A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Authors:  A Ray; Z Tian; D S Das; R L Coffman; P Richardson; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

8.  The resistance mechanisms of proteasome inhibitor bortezomib.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  Biomark Res       Date:  2013-03-01

Review 9.  Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Authors:  Gianfranco Pittari; Luca Vago; Moreno Festuccia; Chiara Bonini; Deena Mudawi; Luisa Giaccone; Benedetto Bruno
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

10.  Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer.

Authors:  Jung-Eun Jang; Cristina H Hajdu; Caroline Liot; George Miller; Michael L Dustin; Dafna Bar-Sagi
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423
View more
  1 in total

1.  Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.

Authors:  Dharminder Chauhan; Kenneth C Anderson; Arghya Ray; Yan Song; Ting Du; Leutz Buon; Yu-Tzu Tai
Journal:  Blood Cancer J       Date:  2022-04-01       Impact factor: 11.037
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.